These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 39493329)
1. Survival outcomes in early-onset oesophageal adenocarcinoma patients: A systematic review and meta-analyses. Russell A; Mitchell S; Turkington RC; Coleman HG World J Gastroenterol; 2024 Oct; 30(38):4221-4231. PubMed ID: 39493329 [TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
3. The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis. Fisher OM; Lord SJ; Falkenback D; Clemons NJ; Eslick GD; Lord RV Gut; 2017 Mar; 66(3):399-410. PubMed ID: 26733670 [TBL] [Abstract][Full Text] [Related]
4. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. den Hoed CM; van Blankenstein M; Dees J; Kuipers EJ Br J Cancer; 2011 Jul; 105(2):200-5. PubMed ID: 21673678 [TBL] [Abstract][Full Text] [Related]
5. Epidemiology and Outcomes of Young-Onset Esophageal Adenocarcinoma: An Analysis from a Population-Based Database. Codipilly DC; Sawas T; Dhaliwal L; Johnson ML; Lansing R; Wang KK; Leggett CL; Katzka DA; Iyer PG Cancer Epidemiol Biomarkers Prev; 2021 Jan; 30(1):142-149. PubMed ID: 33328255 [TBL] [Abstract][Full Text] [Related]
6. Systematic Review of Hypofractionated Radiation Therapy for the Treatment of Oesophageal Squamous Cell Carcinoma and Oesophageal Adenocarcinoma. Sanghera C; McClurg DP; Jones CM Clin Oncol (R Coll Radiol); 2024 Jul; 36(7):430-444. PubMed ID: 38631975 [TBL] [Abstract][Full Text] [Related]
8. Gastro-oesophageal reflux, medical resource utilization and upper gastrointestinal endoscopy in patients at risk of oesophageal adenocarcinoma. Van Soest EM; Dieleman JP; Sturkenboom MC; Siersema PD; Kuipers EJ Aliment Pharmacol Ther; 2008 Jul; 28(1):137-43. PubMed ID: 18373635 [TBL] [Abstract][Full Text] [Related]
9. Loss of SRY-box2 (SOX2) expression and its impact on survival of patients with oesophageal adenocarcinoma. Ten Kate FJC; van Olphen SH; Bruno MJ; Wijnhoven BPL; van Lanschot JJB; Looijenga LHJ; Fitzgerald RC; Biermann K Br J Surg; 2017 Sep; 104(10):1327-1337. PubMed ID: 28692180 [TBL] [Abstract][Full Text] [Related]
10. Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression. Kastelein F; van Olphen SH; Steyerberg EW; Spaander MC; Bruno MJ; Gut; 2016 Apr; 65(4):548-54. PubMed ID: 25903690 [TBL] [Abstract][Full Text] [Related]
11. Young Adults With Esophageal Adenocarcinoma Present With More Advanced Stage Tumors and Have Shorter Survival Times. Sawas T; Manrique GC; Iyer PG; Wang KK; Katzka DA Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1756-1762. PubMed ID: 30267861 [TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: prevalence of prior and concurrent Barrett's oesophagus in oesophageal adenocarcinoma patients. Tan MC; Mansour N; White DL; Sisson A; El-Serag HB; Thrift AP Aliment Pharmacol Ther; 2020 Jul; 52(1):20-36. PubMed ID: 32452599 [TBL] [Abstract][Full Text] [Related]
13. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. Singh S; Garg SK; Singh PP; Iyer PG; El-Serag HB Gut; 2014 Aug; 63(8):1229-37. PubMed ID: 24221456 [TBL] [Abstract][Full Text] [Related]
14. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Desai TK; Krishnan K; Samala N; Singh J; Cluley J; Perla S; Howden CW Gut; 2012 Jul; 61(7):970-6. PubMed ID: 21997553 [TBL] [Abstract][Full Text] [Related]
15. Gastric atrophy and risk of oesophageal cancer and gastric cardia adenocarcinoma--a systematic review and meta-analysis. Islami F; Sheikhattari P; Ren JS; Kamangar F Ann Oncol; 2011 Apr; 22(4):754-760. PubMed ID: 20860989 [TBL] [Abstract][Full Text] [Related]
16. International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Morgan E; Soerjomataram I; Gavin AT; Rutherford MJ; Gatenby P; Bardot A; Ferlay J; Bucher O; De P; Engholm G; Jackson C; Kozie S; Little A; Møller B; Shack L; Tervonen H; Thursfield V; Vernon S; Walsh PM; Woods RR; Finley C; Merrett N; O'Connell DL; Reynolds JV; Bray F; Arnold M Gut; 2021 Feb; 70(2):234-242. PubMed ID: 32554620 [TBL] [Abstract][Full Text] [Related]
18. The incidence of Barrett's oesophagus and oesophageal adenocarcinoma in the United Kingdom and The Netherlands is levelling off. Masclee GM; Coloma PM; de Wilde M; Kuipers EJ; Sturkenboom MC Aliment Pharmacol Ther; 2014 Jun; 39(11):1321-30. PubMed ID: 24738722 [TBL] [Abstract][Full Text] [Related]
19. Non-surgical versus surgical treatment for oesophageal cancer. Best LM; Mughal M; Gurusamy KS Cochrane Database Syst Rev; 2016 Mar; 3(3):CD011498. PubMed ID: 27021481 [TBL] [Abstract][Full Text] [Related]
20. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Turkington RC; Knight LA; Blayney JK; Secrier M; Douglas R; Parkes EE; Sutton EK; Stevenson L; McManus D; Halliday S; McCavigan AM; Logan GE; Walker SM; Steele CJ; Perner J; Bornschein J; MacRae S; Miremadi A; McCarron E; McQuaid S; Arthur K; James JA; Eatock MM; O'Neill R; Noble F; Underwood TJ; Harkin DP; Salto-Tellez M; Fitzgerald RC; Kennedy RD; Gut; 2019 Nov; 68(11):1918-1927. PubMed ID: 30852560 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]